scholarly journals Plasma Levels of snoRNAs are Associated with Platelet Activation in Patients with Peripheral Artery Disease

2019 ◽  
Vol 20 (23) ◽  
pp. 5975
Author(s):  
Anne Yaël Nossent ◽  
Neda Ektefaie ◽  
Johann Wojta ◽  
Beate Eichelberger ◽  
Christoph Kopp ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Peripheral Artery Disease ◽  
Platelet Activation ◽  
Stent Implantation ◽  
Plasma Levels ◽  
Peripheral Artery ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Surgical Interventions ◽  
Artery Disease

In addition to supervised walking therapy, antithrombotic therapy and the management of risk factors, the treatment of peripheral artery disease (PAD) is limited to endovascular and surgical interventions, i.e., angioplasty with stent implantation and bypass surgery, respectively. Both are associated with a high restenosis rate. Furthermore, patients with PAD often suffer atherothrombotic events like myocardial infarction, transient ischemic attacks or stroke. Small ribonucleic acids (RNAs) have proven reliable biomarkers because of their remarkable stability. Small nucleolar RNAs (snoRNAs) guide modifications to small nuclear RNAs and ribosomal RNAs, enabling protein synthesis. In the current study, we measured four snoRNAs in 104 consecutive PAD patients who underwent elective infrainguinal angioplasty with stent implantation. We selected snoRNAs that showed significant overexpression in the plasma of end-stage PAD patients in a previous study. All four snoRNAs are transcribed from the 14q32 locus, which is strongly linked to human cardiovascular disease, including PAD and restenosis. We showed that the four selected 14q32 snoRNAs were abundantly expressed in the plasma of PAD patients. The plasma levels of these snoRNAs were not directly associated with target vessel restenosis, however, levels of SNORD113.2 and SNORD114.1 were strongly linked to platelet activation, which is an important determinant of long-term outcome, in PAD, and in cardiovascular disease in general.

scholarly journals CKD and Acute and Long-Term Outcome of Patients with Peripheral Artery Disease and Critical Limb Ischemia

2015 ◽  
Vol 11 (2) ◽  
pp. 216-222 ◽  
Author(s):  
Florian Lüders ◽  
Holger Bunzemeier ◽  
Christiane Engelbertz ◽  
Nasser M. Malyar ◽  
Matthias Meyborg ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Critical Limb Ischemia ◽  
Limb Ischemia ◽  
Peripheral Artery ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Artery Disease

Restenosis after endovascular revascularization in peripheral artery disease

VASA ◽  
2015 ◽  
Vol 44 (4) ◽  
pp. 257-270 ◽  
Author(s):  
Nasser M. Malyar ◽  
Holger Reinecke ◽  
Eva Freisinger
Keyword(s):  
Peripheral Artery Disease ◽  
Primary Patency ◽  
Lower Limbs ◽  
Lesion Length ◽  
Success Rates ◽  
Peripheral Artery ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Endovascular Revascularization ◽  
Artery Disease

Abstract. Endovascular revascularization (EVR) plays a leading role in the therapy of peripheral artery disease. The acute success rates of EVR in all anatomic territories and of all TASC lesions are excellent (> 95%). However, the occurrence of restenoses after EVR such as percutaneous transluminal angioplasty and particularly after stenting, poses a substantial limitation to the success of the procedure. Influenced by patient’s comorbidities, the severity of arteriosclerotic disease, lesion length and morphology as well as the techniques and devices used for EVR, the long-term outcome of EVR deteriorates markedly from the aortoiliac to the infrapopliteal segments of the lower limbs. The development of drug-coated balloons and drug-eluting stents reduced the occurrence of restenosis leading to considerably improved primary patency rates in the femoropopliteal segments. This review aims to provide an overview about the underlying mechanisms and current relevance of the various options in the field of EVR with regard to the rate of restenosis.

Atrial fibrillation is a risk marker for worse in-hospital and long-term outcome in patients with peripheral artery disease

2015 ◽  
Vol 199 ◽  
pp. 223-228 ◽  
Author(s):  
Kristina Wasmer ◽  
Michael Unrath ◽  
Julia Köbe ◽  
Nasser M. Malyar ◽  
Eva Freisinger ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Peripheral Artery Disease ◽  
Risk Marker ◽  
Peripheral Artery ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Artery Disease

Gender-Related Long-term Outcome of Primary Femoropopliteal Stent Placement for Peripheral Artery Disease

2015 ◽  
Vol 22 (1) ◽  
pp. 31-37 ◽  
Author(s):  
Konstantinos Stavroulakis ◽  
Konstantinos P. Donas ◽  
Giovanni Torsello ◽  
Nani Osada ◽  
Eva Schönefeld
Keyword(s):  
Peripheral Artery Disease ◽  
Stent Placement ◽  
Peripheral Artery ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Artery Disease

A decline in walking distance predicts long-term outcome in patients with known or suspected peripheral artery disease

2009 ◽  
Vol 17 (3) ◽  
pp. 321-328 ◽  
Author(s):  
Inge I. de Liefde ◽  
Ron T. van Domburg ◽  
Jeroen J. Bax ◽  
Jan Klein ◽  
Hence J.M. Verhagen ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Walking Distance ◽  
Peripheral Artery ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Artery Disease

A Targeted Literature Review of the Disease Burden in Patients With Symptomatic Peripheral Artery Disease

Angiology ◽  
2019 ◽  
Vol 71 (4) ◽  
pp. 303-314
Author(s):  
Rupert Bauersachs ◽  
Sebastian Debus ◽  
Mark Nehler ◽  
Maria Huelsebeck ◽  
Janita Balradj ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Disease Burden ◽  
Ankle Brachial Index ◽  
Peripheral Artery ◽  
Economic Burden Of Disease ◽  
Surgical Interventions ◽  
Treatment Practice ◽  
Patient Profile ◽  
Increased Risk ◽  
Artery Disease

Patients with peripheral artery disease (PAD) have an increased risk of cardiovascular (CV) and limb events, but the disease is frequently underdiagnosed and treatment options are limited. This review examines the disease burden of symptomatic PAD as well as key guideline recommendations. Publications were identified using the ProQuest portal to access the Medline, Medline In-Process, and Embase databases. Search terms for symptomatic PAD were combined with terms relevant to epidemiology, burden, treatment practice, and physiopathology. Articles in English published between January 2001 and September 2016 were screened according to the population, interventions, comparator, outcomes, and study design criteria. Relevant publications (n = 200) were identified. The reported incidence and prevalence of PAD varied depending on the definitions used and the study populations. Patients generally had a poor prognosis, with an increased risk of mortality, CV, and limb events and decreased quality of life. Guideline recommendations included ankle–brachial index measurements, exercise testing, and angiography for diagnosis and risk factor modification, antiplatelets, cilostazol, exercise therapy, or surgical interventions for treatment, depending on the patient profile. The clinical, humanistic, and economic burden of disease in patients with symptomatic PAD is substantial and needs to be reduced through improved PAD management.

P938Extensive formation of atherosclerotic cardiovascular disease in subjects with severe familial hypercholesterolemia defined by the international atherosclerosis society criteria

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
S Funabashi ◽  
Y Kataoka ◽  
M Harada-Shiba ◽  
M Hori ◽  
T Doi ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
High Risk ◽  
Familial Hypercholesterolemia ◽  
Peripheral Artery Disease ◽  
Cardiac Death ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Peripheral Artery ◽  
Lowering Therapy ◽  
Artery Disease

Abstract Introduction The International Atherosclerosis Society (IAS) has proposed “severe familial hypercholesterolemia (FH)” as a FH phenotype with the highest cardiovascular risk. Coronary artery disease (CAD) represents a major atherosclerotic change in FH patients. Given their higher LDL-C level and atherogenic clinical features, more extensive formation of atherosclerosis cardiovascular disease including not only CAD but stroke/peripheral artery disease (PAD) may more frequently occur in severe FH. Methods 481 clinically-diagnosed heterozygous FH subjects were analyzed. Severe FH was defined as untreated LDL-C>10.3 mmol/l, LDL-C>8.0 mmol/l+ 1 high-risk feature, LDL-C>4.9 mmol/l + 2 high-risk features or presence of clinical ASCVD according to IAS proposed statement. Cardiac (cardiac death and ACS) and non-cardiac (stroke and peripheral artery disease) events were compared in severe and non-severe FH subjects. Results Severe FH was identified in 50.1% of study subjects. They exhibit increased levels of LDL-C and Lipoprotein (a) with a higher frequency of LDLR mutation. Furthermore, a proportion of %LDL-C reduction>50% was greater in severe FH under more lipid-lowering therapy (Table). However, during the observational period (median=6.3 years), severe FH was associated with a 5.9-fold (95% CI, 2.05–25.2; p=0.004) and 5.8-fold (95% CI, 2.02–24.7; p=0.004) greater likelihood of experiencing cardiac-death/ACS and stroke/PAD, respectively (picture). Multivariate analysis demonstrated severe FH as an independent predictor of both cardiac-death/ACS (hazard ratio=3.39, 95% CI=1.12–14.7, p=0.02) and stroke/PAD (hazard ratio=3.38, 95% CI=1.16–14.3, p=0.02) events. Clinical characteristics of severe FH Non-severe FH Severe FH P-value Baseline LDL-C (mmol/l) 5.3±1.5 6.6±2.0 <0.0001 Lp(a) (mg/dl) 15 [8–28] 21 [10–49] <0.0001 LDLR mutation (%) 49.6% 58.9% 0.00398 On-treatment LDL-C (mmol) 133 [106–165] 135 [103–169] 0.9856 %LDL-C reduction>50% 21.3% 49.8% <0.0001 High-intensity statin (%) 13.3% 42.3% <0.0001 PCSK9 inhibitor (%) 6.3% 21.2% <0.0001 Clinical outcome Conclusions Severe FH subjects exhibit substantial atherosclerotic risks for coronary, carotid and peripheral arteries despite lipid lowering therapy. Our finding underscore the screening of systemic arteries and the adoption of further stringent lipid management in severe FH patients.

Renal function and short-term outcome in stable outpatients with coronary, cerebrovascular or peripheral artery disease

2013 ◽  
Vol 229 (1) ◽  
pp. 258-262 ◽  
Author(s):  
Davide Bernaudo ◽  
Ramón Coll ◽  
Juan F. Sánchez Muñoz-Torrero ◽  
María Teresa Pascual ◽  
Ana María García-Díaz ◽  
...  
Keyword(s):  
Renal Function ◽  
Peripheral Artery Disease ◽  
Peripheral Artery ◽  
Short Term ◽  
Term Outcome ◽  
Short Term Outcome ◽  
Artery Disease
Sign in / Sign up

Export Citation Format

Share Document